{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Macular+Neovascularization+Secondary+to+Age-Related+Macular+Degeneration",
    "query": {
      "condition": "Macular Neovascularization Secondary to Age-Related Macular Degeneration"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 29,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Macular+Neovascularization+Secondary+to+Age-Related+Macular+Degeneration&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T10:32:29.732Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00767949",
      "title": "Safety Study of iSONEP (Sonepcizumab/LT1009) to Treat Neovascular Age-related Macular Degeneration",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neovascular Age Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "iSONEP",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Lpath, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2008-10",
      "completion_date": "2012-08",
      "has_results": false,
      "last_update_posted_date": "2012-04-16",
      "last_synced_at": "2026-10-10T10:32:29.732Z",
      "location_count": 5,
      "location_summary": "Phoenix, Arizona • Winter Haven, Florida • Indianapolis, Indiana + 2 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Winter Haven",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00767949"
    },
    {
      "nct_id": "NCT00766337",
      "title": "Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Age-Related Macular Degeneration",
        "Choroidal Neovascularization"
      ],
      "interventions": [
        {
          "name": "Sirolimus in combination with ranibizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo in combination with ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Santen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2008-12",
      "completion_date": "2010-03",
      "has_results": false,
      "last_update_posted_date": "2013-01-10",
      "last_synced_at": "2026-10-10T10:32:29.732Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00766337"
    },
    {
      "nct_id": "NCT03452527",
      "title": "Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Choroidal Neovascularization",
        "Wet Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "ICON-1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "aflibercept",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Iconic Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2018-03-26",
      "completion_date": "2019-04-25",
      "has_results": true,
      "last_update_posted_date": "2021-04-13",
      "last_synced_at": "2026-10-10T10:32:29.732Z",
      "location_count": 8,
      "location_summary": "Beverly Hills, California • Santa Ana, California • Syracuse, New York + 5 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "Syracuse",
          "state": "New York"
        },
        {
          "city": "Ashland",
          "state": "Oregon"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03452527"
    },
    {
      "nct_id": "NCT00403156",
      "title": "Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Choroidal Neovascularization"
      ],
      "interventions": [
        {
          "name": "Imatinib Mesylate /Ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vitreous -Retina- Macula Consultants of New York",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "51 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "51 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2006-11",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2015-12-31",
      "last_synced_at": "2026-10-10T10:32:29.732Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00403156"
    },
    {
      "nct_id": "NCT03823300",
      "title": "A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Wet Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Faricimab",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept",
          "type": "DRUG"
        },
        {
          "name": "Sham Procedure",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 658,
      "start_date": "2019-03-11",
      "completion_date": "2022-01-07",
      "has_results": true,
      "last_update_posted_date": "2025-07-11",
      "last_synced_at": "2026-10-10T10:32:29.732Z",
      "location_count": 41,
      "location_summary": "Phoenix, Arizona • Mountain View, California • Sacramento, California + 36 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Mountain View",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03823300"
    },
    {
      "nct_id": "NCT00695682",
      "title": "Intravitreal Infliximab for Diabetic Macular Edema (DME) and Choroidal Neovascularization (CNV)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetic Retinopathy",
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "intravitreal injection of infliximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Retina Research Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 4,
      "start_date": "2008-06",
      "completion_date": "2008-12",
      "has_results": false,
      "last_update_posted_date": "2008-06-12",
      "last_synced_at": "2026-10-10T10:32:29.732Z",
      "location_count": 1,
      "location_summary": "Slingerlands, New York",
      "locations": [
        {
          "city": "Slingerlands",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00695682"
    },
    {
      "nct_id": "NCT03823287",
      "title": "A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Wet Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Faricimab",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept",
          "type": "DRUG"
        },
        {
          "name": "Sham Procedure",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 671,
      "start_date": "2019-02-19",
      "completion_date": "2022-01-18",
      "has_results": true,
      "last_update_posted_date": "2025-07-23",
      "last_synced_at": "2026-10-10T10:32:29.732Z",
      "location_count": 52,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Campbell, California + 47 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Campbell",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03823287"
    },
    {
      "nct_id": "NCT00426998",
      "title": "Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Choroidal Neovascularization",
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Verteporfin",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Retinal Consultants Medical Group",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2006-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2007-01-26",
      "last_synced_at": "2026-10-10T10:32:29.732Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00426998"
    },
    {
      "nct_id": "NCT00242580",
      "title": "A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Macular Degeneration",
        "Choroidal Neovascularization"
      ],
      "interventions": [
        {
          "name": "Verteporfin photodynamic therapy",
          "type": "DRUG"
        },
        {
          "name": "Pegaptanib",
          "type": "DRUG"
        },
        {
          "name": "Triamcinolone acetonide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 111,
      "start_date": "2005-09",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2016-03-31",
      "last_synced_at": "2026-10-10T10:32:29.732Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00242580"
    },
    {
      "nct_id": "NCT00090623",
      "title": "A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "rhuFab V2 (ranibizumab)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 180,
      "start_date": "2004-08",
      "completion_date": "2007-03",
      "has_results": false,
      "last_update_posted_date": "2013-06-21",
      "last_synced_at": "2026-10-10T10:32:29.732Z",
      "location_count": 1,
      "location_summary": "Denver, Colorado",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00090623"
    }
  ]
}